BRINSUPRI™: A Beginning for the Bronchiectasis Community

“This multi-modality strategy has long been the standard for other chronic diseases, such as congestive heart failure, and bronchiectasis warrants an equally nuanced approach.” Dr. PJ McShane

Some people have now been on BRINSUPRI™ for a month or two, and we are beginning to hear early feedback. It is always encouraging to learn that someone’s quality of life has improved with more energy and less breathlessness.

At the same time, others have not yet noticed a difference, and a few have stopped taking the medication for various reasons.

This is why it is important to share recent comments from Dr. PJ McShane, one of the leading bronchiectasis experts at the National Institutes of Health (NIH).

In a recent Archivos de Bronconeumologia editorial, Dr. McShane describes BRINSUPRI, as a breakthrough for the bronchiectasis community and as an important step forward in reducing inflammation and exacerbations for people living with bronchiectasis.

However, she emphasizes that it’s unrealistic to expect one drug to meet every patient’s needs. Instead, she encourages both clinicians and patients to view BRINSUPRI™ as part of a broader treatment plan that includes mucoactive agents, airway-clearance techniques, and, when appropriate, macrolide therapy.

She made similar remarks during an unrecorded Bronchiectasis and NTM Association support group meeting, which many of us found insightful.

Bronchiectasis is a complex condition, and many people may benefit from a multi-pronged approach that also targets mucus properties and airway inflammation. Other chronic diseases require combination therapy to achieve optimal results, and it is reasonable to assume that bronchiectasis may be similar.

Progress takes time, and each person’s journey will look a little different.

Editorial: P.J. McShane, Are Dipeptidyl Peptidase-1 Inhibitors the Future Anti-inflammatory Treatment in Bronchiectasis? Archivos de Bronconeumología, https://doi.org/10.1016/j.arbres.2025.09.002